Table 1. Correlation between MBP-1 expression and clinicopathological characteristics of breast cancer patients.
| Variable | Total (%) | MBP-1 nuclear immunoreactivity | P | |
| Positive (%) | Negative (%) | |||
| Age (yr) | ||||
| ≤50 | 51 (29) | 15 (23) | 36 (32) | |
| >50 | 126 (71) | 51 (77) | 75 (68) | NS |
| Tumor size | ||||
| ≤2 cm | 68 (38) | 28 (42) | 40 (36) | |
| >2 cm | 109 (62) | 38 (58) | 71 (64) | NS |
| Node status | ||||
| negative | 85 (48) | 44 (67) | 41 (37) | |
| positive | 92 (52) | 22 (23) | 70 (63) | 0.0002 |
| Tumor grade | ||||
| 1–2 | 80 (45) | 43 (65) | 37 (33) | |
| 3–4 | 97 (55) | 23 (35) | 74 (67) | <0.0001 |
| ErbB2 | ||||
| negative | 122 (69) | 58 (88) | 64 (58) | |
| positive | 55 (31) | 8 (12) | 47 (52) | <0.0001 |
| ER | ||||
| negative | 39 (26) | 15 (59) | 24 (25) | |
| positive | 112 (74) | 41 (61) | 71 (75) | NS |
| PG | ||||
| negative | 57 (38) | 16 (29) | 41 (43) | |
| positive | 94 (62) | 40 (71) | 54 (57) | NS |
| Ki67 | ||||
| negative | 33 (19) | 19 (29) | 14 (13) | |
| positive | 144 (81) | 47 (71) | 97 (87) | 0.0096 |
| Recurrences | ||||
| recurrent | 32 (40) | 4 (17) | 28 (51) | |
| non recurrent | 47 (60) | 20 (83) | 27 (49) | 0.0057 |
| Death for disease | ||||
| Yes | 19 (24) | 3 (13) | 16 (29) | |
| No | 60 (76) | 21 (87) | 39 (71) | NS |
NOTE: Statistical analyses were done by the Fisher's exact test. A P value of <0.05 was considered significant.
Abbreviations: ER, estrogen receptor; PG, progesterone receptor;
NS, nonsignificant.